Related by context. All words. (Click for frequent words.) 71 Phase 2b Clinical Trial 70 Pafuramidine 69 oral dual endothelin 69 nucleotide analogue 69 Epratuzumab 69 Heterozygous Familial Hypercholesterolemia 69 Complicated Skin 68 CYT# potent vascular disrupting 68 Aflibercept 68 Pivotal Phase III 68 MAGE A3 ASCI 68 Vicriviroc 68 R Saizen R 68 SPRYCEL ® 68 Meets Primary Endpoint 68 delivers fluocinolone acetonide FA 68 fosbretabulin 68 evaluating tivozanib 68 Silodosin 68 INCB# [003] 67 Randomized Double blind 67 telomerase therapeutic 67 erlotinib Tarceva ® 67 Enzastaurin 67 Zorbtive TM 67 oral prodrug 67 Hsp# Inhibitor 67 systemic juvenile idiopathic 67 Pooled Analysis 67 Initiates Phase III 67 Tolvaptan 67 Previously Untreated 67 canakinumab 67 sorafenib tablets 67 Relapsing Multiple Sclerosis 67 Diabetic Macular Edema 67 MKC# MKC# PP 67 recurrent glioblastoma multiforme 67 FDA APPROVES 67 Severe Sepsis 67 Elotuzumab 66 Safinamide 66 Ophena TM 66 PEGINTRON TM 66 sorafenib Nexavar 66 Prolongs Survival 66 methylnaltrexone bromide 66 Patients Treated With 66 Phase III Clinical Trial 66 Myelodysplastic Syndrome MDS 66 Tanespimycin 66 FOLOTYN ® 66 pediatric malignancies 66 Antitumor Activity 66 Sapacitabine 66 Study Evaluating 66 relapsed MM 66 Fondaparinux 66 BRIM2 66 Mg Usa 66 novel VDA molecule 66 Prospective Randomized 66 acetonide FA 66 induced macular edema 66 Valsartan 66 CLARITY TIMI 66 Temsirolimus 66 Paxil paroxetine 66 Investigational Treatment 66 HuMax EGFr 66 Combination REOLYSIN R 66 ALN HPN 66 Peginterferon 66 Deforolimus 66 Initiates Phase II 66 JAK Inhibitor 66 Ridaforolimus 65 virus HCV protease inhibitor 65 recurrent metastatic ovarian cancer 65 thalidomide Thalomid 65 ZOLINZA 65 Elagolix 65 Phase 2b Study 65 Efficacy Trial 65 Pemetrexed 65 Oral Fingolimod 65 ritonavir boosted 65 R lenalidomide 65 Romidepsin 65 Controlled Trial 65 Advanced Melanoma 65 Tezampanel 65 multicenter Phase III 65 hypereosinophilic syndrome 65 ULORIC 65 Phase 2b Trial 65 Aliskiren 65 Tocilizumab 65 severe hypercholesterolemia 65 Initiates Enrollment 65 treat benign prostatic 65 receptor tyrosine kinase inhibitor 65 Syncria R 65 Phase IIb Trial 65 Navelbine ® 65 ELADUR ™ 65 Diabetic Nephropathy 65 Golimumab 65 BCG refractory carcinoma 65 nucleoside analog 65 advanced metastatic renal 65 pseudobulbar affect PBA 65 Forodesine HCl 65 reslizumab 65 PKC# 65 catheter occlusion 65 cilengitide 65 dextromethorphan quinidine 65 Liprotamase 65 Eculizumab 65 APEX PD 65 metastatic colorectal 65 dasatinib Sprycel ® 65 non nucleoside inhibitor 65 Novel Oral 65 Intervention Effectiveness 65 MKC# MT 65 MEK Inhibitor 65 visilizumab 65 Glufosfamide 65 Demonstrates Positive 65 CTAP# 65 Investigational Compound 65 colesevelam HCl 65 undergoing elective percutaneous 65 Bazedoxifene 65 alvespimycin 65 Granted Orphan Drug 65 Advanced Renal Cell 65 FOLFOX6 chemotherapy regimen 65 Paraplatin ® 65 oncolytic virus therapies 65 Dasatinib 65 Completes Patient Enrollment 65 Initiate Phase 65 acyclovir Lauriad R 65 EDEMA3 65 Prostate AdenoCarcinoma Treatment 65 lexidronam injection 65 Chronic Hepatitis C 65 IL# PE#QQR 65 Pulmonary Arterial Hypertension 65 trastuzumab Herceptin R 65 Paroxysmal Nocturnal Hemoglobinuria PNH 65 Dapagliflozin 65 Enzyme Replacement Therapy 64 Ziprasidone 64 5 fluorouracil leucovorin 64 topically applied SEPA 64 Trandolapril 64 small molecule Hedgehog 64 topiramate Topamax 64 HMG CoA reductase inhibitors 64 fluvastatin 64 Bipolar Mania 64 RNAi Therapeutic 64 orally administered inhibitor 64 Luteinizing Hormone Releasing Hormone 64 Ranolazine 64 forodesine 64 Mg Uk 64 Pancreas Cancer Vaccine 64 alfa 2a 64 Bucindolol 64 BZA CE 64 refractory chronic lymphocytic 64 Tarceva TM 64 GOUT 64 Tyrosine Kinase Inhibitor 64 Pertuzumab 64 LAB CGRP 64 candesartan cilexetil 64 TNF Tumor Necrosis Factor 64 Hypoactive Sexual Desire Disorder 64 Telithromycin 64 Calcium Acetate 64 II Clinical Trial 64 monoclonal antibody conjugated 64 Anti Tumor 64 CINQUIL 64 Tipranavir 64 systemic anaplastic large 64 Relapsed Refractory 64 Ozarelix 64 BARACLUDE ® 64 Methylnaltrexone 64 serotonin norepinephrine reuptake inhibitor 64 Tigecycline 64 Anti VEGF 64 histone deacetylase HDAC inhibitor 64 AVASTIN 64 Bosutinib 64 demonstrated antitumor activity 64 Agonist MABA program 64 Degarelix 64 albiglutide 64 atypical Hemolytic Uremic Syndrome 64 Romiplostim 64 huC# DM4 64 TRANSDUR ® 64 JAK2 Inhibitor 64 PEGylated anti 64 Non inferiority 64 phase III isavuconazole 64 Rotavirus Vaccine 64 AFREZZA TM 64 keloid scarring 64 Monoclonal Antibody 64 Mycophenolate Mofetil 64 abacavir sulfate lamivudine 64 cell lymphoma CTCL 64 Pivotal Study 64 Capesaris 64 Darinaparsin 64 Clolar ® 64 kidney urologic 64 selective modulator 64 dependent kinase inhibitor 64 Interferon beta 1a 64 Soft Tissue Sarcoma 64 Previously Treated 64 acadesine 64 Monotherapy 64 Oral Formulation 64 ORENCIA ® 64 NSABP B 64 ospemifene 64 Novel Antibiotic 64 ziprasidone Geodon 64 aripiprazole Abilify 64 tarenflurbil 64 Belimumab 64 riociguat 64 Transdermal Patch 64 evaluating mipomersen 64 Vidaza ® 64 DU #b 64 Adenoma Prevention 64 PRN FDA Approves 64 Vildagliptin 64 5 Fluorouracil 64 Kuvan sapropterin dihydrochloride 64 Pimavanserin 64 Ambrisentan 64 Elvitegravir 64 pan histone deacetylase 64 Preclinical Models 64 Azacitidine 64 AVAPRO 64 ACTEMRA TM 64 Chronic Myeloid Leukemia 64 gefitinib Iressa 64 investigational oral inhibitor 64 metastatic castration resistant 64 Receives Orphan Drug Designation 64 Iluvien TM 64 mesylate 64 Raptiva ® 64 Newly Diagnosed Multiple Myeloma 64 First Patient Enrolled 64 Randomized Phase 64 Kinase Inhibitor 64 Bicalutamide 64 TMC# C# 64 Tesetaxel 64 Combination Treatment 64 Cholesterol Levels SPARCL 64 Squalamine 63 pralatrexate injection folate analogue 63 Xeloda ® 63 number NCT# ClinicalTrials.gov 63 Recurrent Glioblastoma 63 Omacetaxine 63 Solazed TM 63 Glycopyrrolate 63 highly selective endothelin 63 Adalimumab 63 Pivotal Trial 63 neratinib 63 itraconazole Sporanox 63 aflibercept VEGF Trap 63 Long Term Efficacy 63 Linagliptin 63 JAK inhibitor 63 leukotriene receptor antagonists 63 induce orthostatic hypotension 63 BRIM3 63 See CLINICAL PHARMACOLOGY 63 Refractory Angina 63 sunitinib Sutent ® 63 intravitreal insert 63 Diabetic Neuropathy 63 Initiate Clinical Trial 63 brand ciclesonide HFA 63 DEB# 63 relapsing remitting MS RRMS 63 Cerebril TM 63 Phase III Pivotal 63 blinded randomized placebo controlled 63 Primary Hypercholesterolemia 63 Cutaneous T 63 Presents Preclinical Data 63 TO AVOID PREGNANCY WHILE 63 STRIDE PD 63 Begins Dosing 63 Clinical Trial Results 63 Ovitrelle R Serostim 63 5 FU leucovorin 63 ribavirin USP 63 Inhalation Aerosol 63 ADVANCE PD 63 pan HDAC inhibitor 63 ergot derivatives 63 CYP#A# substrate 63 Benign Prostatic Hyperplasia 63 Nilotinib 63 Nitazoxanide 63 registrational Phase 63 Onyx Pharmaceuticals Announces 63 metastatic malignant 63 Engerix B 63 Medoxomil 63 ToGA 63 TLK# 63 Refractory Hodgkin Lymphoma 63 complement inhibitor eculizumab 63 docetaxel Taxotere ® 63 randomized controlled multicenter 63 oropharyngeal candidiasis OPC 63 Pivotal Phase 63 metformin HCl 63 metaglidasen 63 cisplatin gemcitabine 63 TNF Blockers 63 sodium glucose cotransporter 63 Telmisartan 63 interferon beta 1a infertility 63 Renal Impairment 63 Randomized Phase II 63 Vitrasert R 63 dihydroergotamine 63 de novo kidney transplant 63 Acute Ischemic Stroke 63 R sorafenib tablets 63 Glatiramer Acetate 63 Aggressive Reduction 63 First Patient Dosed 63 pertuzumab 63 Vandetanib 63 Betaferon R 63 investigational antiplatelet agent 63 #I TM# 63 Diabetic Macular Edema DME 63 Recombinant Human 63 Saizen ® 63 Eluting Stent 63 herpetic keratitis 63 phase IIb clinical 63 Muraglitazar 63 antibody MAb 63 Fixed Dose 63 MKC# 63 By JENNIFER LEARN 63 Reminyl galantamine 63 Sipuleucel T 63 SUPPRELIN R LA 63 Celebrex celecoxib 63 Catena ® 63 hyperplasia BPH 63 Investigational Drug 63 Initiates Clinical Trial 63 Ropinirole 63 ExTRACT TIMI 63 ALVESCO ® 63 Zenvia ™ 63 ThermoDox ® clinical 63 vapreotide acetate 63 Completes Enrollment 63 ZACTIMA 63 Relapsed Multiple Myeloma 63 EPIVIR 63 nilotinib Tasigna 63 Adjunctive Therapy 63 IMiDs ® 63 intranasal formulation 63 Dupuytren Disease 63 sapropterin dihydrochloride 63 abacavir Ziagen 63 adalimumab Humira 63 COPEGUS R 63 relapsed refractory multiple myeloma 63 intravesical infusion therapy 63 RELOVAIR ™ 63 Valopicitabine 63 arsenic trioxide injection 63 EURIDIS 63 LHRH receptor positive 63 Phase III Clinical Trials 63 EnteroMedics proprietary neuroblocking technology 63 Metabolic Efficiency 63 Medidur TM FA 63 LymphoStat B TM 63 YONDELIS 63 Non Alcoholic Steatohepatitis 63 buccal tablets 63 Pegylated Interferon 63 EOquin TM phase 63 oral ghrelin agonist 63 insulin glulisine 63 Double Blind Placebo 63 atypical hemolytic uremic syndrome 63 hoFH 63 Fabry Disease 63 Preclinical Data 63 sertraline Zoloft 63 included exfoliative dermatitis 63 myelodysplastic myeloproliferative diseases 63 Treatment Experienced 63 Monopril 63 GW# [003] 62 Phase Ib clinical 62 Unstable Angina 62 highly selective inhibitor 62 combines bupropion 62 superficial bladder cancer 62 ASTEROID 62 lapatinib Tykerb 62 Cloretazine 62 Pharmacokinetics PK 62 Commences Phase 62 INSPIRE Trial Phase III 62 AA Amyloidosis 62 rivastigmine Exelon 62 either acutely decompensated 62 lintuzumab SGN 62 cromolyn sodium 62 Tiotropium 62 LUX Lung 62 Immunotherapeutic 62 oral nucleoside analogue 62 Peginterferon alfa 2b 62 Etanercept 62 Frozen Shoulder syndrome Adhesive 62 miconazole Lauriad ® 62 HGS ETR1 mapatumumab 62 IMA# 62 Phase IIb Clinical Trial 62 Eltrombopag 62 Plecanatide 62 Hepatocellular Carcinoma HCC 62 phase IIIb 62 Microalbuminuria 62 Ceflatonin 62 Fluconazole 62 Albuferon TM 62 Daclizumab 62 imipramine Tofranil 62 mertansine 62 Ribavirin causes 62 Humanized Anti 62 Phase 2a Clinical Trial 62 Randomized Double Blind 62 Relapsing Remitting Multiple Sclerosis 62 Pegloticase 62 Hormone Refractory Prostate Cancer 62 ® lenalidomide 62 Protease Inhibitor 62 icatibant 62 Fast Track Status 62 Overactive Bladder 62 Improves Outcomes 62 Maribavir 62 cutaneous T 62 risperidone Risperdal 62 UPLYSO 62 HCV SPRINT 62 dihydrochloride 62 Arranon 62 Triapine 62 midstage clinical 62 mGluR5 negative 62 Nebulized 62 nephropathic cystinosis 62 Plenaxis TM 62 multicenter randomized controlled 62 myelofibrosis polycythemia vera 62 Demonstrates Sustained 62 1mg 2mg 62 Pyridorin 62 Hepatotoxicity 62 refractory cutaneous T 62 Successfully Completes Phase 62 rosuvastatin Crestor 62 LEVAQUIN 62 Phase IIa Clinical Trial 62 MGd 62 HDAC Inhibitor 62 indolent follicular non 62 polycythemia vera PV 62 Treatment Resistant 62 Dupuytren Contracture 62 Hydrochlorothiazide Tablets 62 Community Acquired Pneumonia 62 Afatinib 62 Metastatic Melanoma 62 Curaxin CBLC# 62 EXPLORE Xa 62 Personalized Immunotherapy 62 dose escalation clinical 62 thiazolidinedione TZD 62 AEGR 62 PrevOnco 62 bone marrow reticulin deposition 62 eosinophilic asthma 62 Commence Phase 62 Adjuvant Treatment 62 phase Ib clinical 62 Nymox NX 62 vinca alkaloid 62 LibiGel ® 62 modified glutathione analog 62 galiximab 62 Amgen Neulasta R 62 oral ridaforolimus 62 Epidermal Growth Factor Receptor 62 Trial Evaluating 62 terlipressin 62 Lanthanum Carbonate 62 Dalbavancin 62 Initiates Clinical 62 investigational protease inhibitor 62 Presents Positive 62 PNP inhibitor 62 formerly LymphoStat B 62 liposomal formulation 62 oral Janus kinase 62 Severe Asthma 62 Investigational Oral 62 Dose Ranging Study 62 administered concomitantly 62 Rosuvastatin 62 selective androgen receptor modulator 62 Febuxostat 62 budesonide foam 62 homozygous familial hypercholesterolemia 62 Mylan Receives Approval 62 Val HeFT 62 Carbamazepine 62 post herpetic neuralgia PHN 62 Achieves Primary Endpoint 62 Ramelteon 62 vinorelbine tartrate 62 NICE Recommends 62 imatinib Gleevec ® 62 Cholesterol Lowering Drug 62 Myelodysplastic Syndrome 62 paclitaxel poliglumex 62 Aryplase 62 VEGFR2 inhibitor 62 Hormone Receptor Positive 62 Qutenza TM 62 Teva Provides Update 62 mGluR2 positive 62 relapsing multiple sclerosis 62 HCV RESPOND 2 62 liposomal amphotericin B 62 LymphoStat B belimumab 62 stage IIIB 62 targeted radiotherapeutic 62 Moxifloxacin 62 Preclinical Study 62 benign prostatic hypertrophy BPH 62 TRANSDUR ™ 62 pregabalin Lyrica 62 Tasigna nilotinib 62 Hepatocellular Carcinoma 62 Well Tolerated 62 systemic RNAi therapeutic 62 essential thrombocythemia ET 62 NS5B polymerase 62 Statistically Significant 62 PDX pralatrexate 62 Denufosol 62 retinal vein occlusion induced 62 tenofovir Viread 62 Therapeutic Vaccine 62 Neovascular Age Related Macular 62 Fulvestrant 62 Ozurdex 62 headache abdominal pain 62 Sevelamer 62 Fluvastatin 62 Phase #b/#a clinical 62 AERIUS 62 rHuPH# recombinant human 62 Drug Candidate 62 CONQUER OB 62 Carbidopa Levodopa 62 FUSILEV ® 62 Carotid Revascularization Endarterectomy vs. 62 candidates Azedra TM 62 proteasome inhibitor 62 Actonel risedronate 62 Avanafil 62 Allergic Rhinitis 62 velafermin 62 Myelofibrosis 62 Single Dose 62 pharmacokinetic PK study 62 Parnate 62 MetroGel 62 Demonstrates Efficacy 62 hormone refractory metastatic prostate 62 Files IND 62 Coadministration 62 Mipomersen 62 Acute Decompensated Heart Failure 62 receiving INTRON 62 unique alkylating agent 62 NMDA antagonist 62 Anturol TM 62 paroxetine sertraline 62 Nesiritide 62 Platelet Inhibition 62 erythematosus SLE 62 DIRECT Trial 62 CHAMPION PCI 62 flavopiridol 61 Xcytrin R 61 metastatic colorectal carcinoma 61 FEMALES SHOULD BE ADVISED 61 bevacizumab Avastin 61 phase IIb study 61 docetaxel Taxotere R 61 beta 1a 61 oral rivaroxaban 61 tenofovir TDF 61 oral dihydropyrimidine dehydrogenase DPD 61 Angiotensin Converting Enzyme 61 GVAX ® 61 IgG1 monoclonal antibody 61 Pivotal Phase II 61 Metastatic Prostate Cancer 61 Resistant Hypertension 61 Fingolimod 61 OMP #R# 61 polymerase inhibitor 61 BENLYSTA TM 61 Rheumatoid Arthritis RA 61 paclitaxel Taxol R 61 Fluorouracil 61 Sprycel dasatinib 61 dual endothelin receptor antagonist 61 chronic eosinophilic leukemia 61 Chronic Lymphocytic Leukemia 61 Iloperidone 61 STELARA TM 61 occlusion PAO 61 ONTARGET 61 efavirenz EFV 61 Receives Approvable Letter 61 Shows Promise Against 61 NOMID 61 GSK# [001] 61 meropenem 61 SANTE 61 papillary renal cell carcinoma 61 Quinamed 61 Kepivance 61 Seliciclib CYC# 61 phase IIb trial 61 allosteric modulator NAM 61 DDP# 61 HCD# [002] 61 bortezomib Velcade 61 EDEMA4 61 HuMax 61 Vidaza azacitidine 61 PEGylated Fab fragment 61 Cloretazine ® 61 Leukemias 61 Testosterone MDTS R 61 Polyneuropathy 61 Daptomycin 61 palifermin 61 TACI Ig 61 Patient Enrollment 61 AFREZZA ™ 61 Long Lesion 61 Proellex TM 61 Treatment Naïve 61 constipation OIC 61 Known hypersensitivity 61 Zarnestra 61 INS# [001] 61 peginterferon alpha 2a 61 Improves Survival 61 SUTENT ® 61 Loceryl ® 61 Diffuse Large B 61 XYZAL R 61 selective antagonist 61 AKT inhibitor 61 Toremifene 61 Pharmacokinetic Study 61 Microplasmin 61 Lubiprostone 61 lead Aganocide compound 61 Initiates Phase 61 Therapeutic Efficacy 61 CYP#A# CYP#D# 61 Pazopanib 61 relapsed leukemia 61 multicenter Phase II 61 ROTARIX 61 oral proteasome inhibitor 61 Phase 1a clinical 61 efaproxiral 61 Pagoclone 61 radiolabeled TM# 61 Phase Ib II 61 Tyrima 61 acute humoral rejection 61 nilotinib Tasigna ® 61 Teriflunomide 61 Levetiracetam 61 severe hypersensitivity reactions 61 naïve HCV 61 HER2 Positive Breast Cancer 61 FUSILEV enhances 61 Antitumor 61 NDA Submission 61 Eraxis 61 Adjuvant Chemotherapy 61 heparin induced thrombocytopenia 61 non peptidic protease 61 non splenectomized 61 Confirms Efficacy 61 Paliperidone Palmitate 61 Placebo Controlled 61 non resectable metastatic 61 Preclinical Efficacy 61 Pirfenidone 61 DAVANAT 61 Dabigatran etexilate 61 Abacavir 61 treat chronic sinusitis 61 Interferon Beta 61 Controlled Study 61 Gamunex C 61 weekly subcutaneous injections 61 Celecoxib APC trial 61 R roscovitine CDK cyclin 61 PEGylated interferon beta 1a 61 inhibitor RG# 61 Idiopathic Pulmonary Fibrosis 61 chronic myeloid 61 Oral Calcitonin 61 Blinatumomab 61 rALLy 61 denileukin diftitox 61 Desvenlafaxine 61 Oral Spray 61 alpha 2a 61 Bronchiectasis 61 etanercept Enbrel 61 Capsules CII 61 Initiated Phase 61 Emtriva Viread 61 teriflunomide 61 Rigel R# 61 selective A2A adenosine receptor 61 candidates Azedra 61 Hedgehog Pathway Inhibitor 61 worsening thrombocytopenia 61 NASH Huntington 61 Melphalan 61 R bendamustine hydrochloride 61 pulmonary hypertension PH 61 trastuzumab Herceptin ® 61 Cell Lymphoma 61 Is Well Tolerated 61 Geodon ziprasidone 61 alefacept 61 AVOREN 61 GRNOPC1 contains 61 refractory indolent non 61 Central Retinal Vein 61 decompensated liver disease 61 ThermoDox R 61 Eszopiclone 61 SPL# Gel vaginal microbicide 61 DNAwithPap TM Test 61 investigational monoclonal antibody 61 hyaluronidase enzyme 61 severe gastroparesis 61 ATACAND 61 ATRA IV 61 Darapladib 61 Potent Antiviral Activity 61 Inhalation Solution 61 Femara letrozole 61 headache nasopharyngitis 61 basiliximab 61 REPRONEX ® menotropins 61 pentostatin 61 Renal Cell Carcinoma 61 metastatic gastric 61 HCV Protease Inhibitor 61 Sustained Efficacy 61 pioglitazone HCl 61 Multicenter Randomized 61 Motesanib 61 interleukin IL -# 61 Hypercholesterolemia 61 inhalation aerosol 61 Gilead Viread 61 lucinactant 61 treatment naive genotype 61 Prilosec omeprazole 61 AAG geldanamycin analog 61 Saxagliptin 61 finasteride Proscar 61 multicentre randomized 61 Novel Mechanism 61 mGluR5 NAM 61 Warner Chilcott Actonel 61 Platinol ® 61 developing Bicifadine serotonin 61 Double Blind Randomized 61 Abrupt discontinuation 61 gastrointestinal stromal tumors GIST 61 mTOR inhibitor 61 Aganocide ® 61 metastatic castrate resistant 61 Systemic Sclerosis 61 orally inhaled migraine 61 Aviptadil 61 protein tyrosine phosphatase 1B 61 RoACTEMRA 61 Lenocta TM 61 subependymal giant cell 61 Dementia Related Psychosis 61 Bucindolol Based 61 Cannabinor 61 Clinical Trial Evaluating 61 lamotrigine Lamictal 61 insulin aspart 61 Cethromycin 61 stage IIIb 61 Zenvia Phase III 61 indinavir Crixivan 61 Myelodysplastic Syndromes 61 Femring ® 61 Roche Boniva 61 Oral Insulin 61 Demonstrates Potent 61 Xelox 61 Submits NDA 61 anti arrhythmic drug 61 MEND CABG 61 Peginterferon Alfa 2a 61 HDL Selective Delipidation 61 Alemtuzumab 61 Cancidas 61 Hematologic 61 Aplidin 61 acetylcholinesterase inhibitor 61 Levoleucovorin 61 severe oral mucositis 61 topical gel formulation 61 XYOTAX TM 61 Plaquenil 61 Solagé 61 Aeolus Pharmaceuticals Announces 61 Multiple Myeloma MM 61 metastatic GIST 61 mapatumumab 60 CRLX# 60 ACE Inhibitors 60 Carvedilol 60 Acute Myocardial Infarction 60 Cardiotoxicity 60 Immunomodulatory 60 Phase IIIb clinical 60 #mg/#mg 60 Pralatrexate 60 Thromboembolism 60 metastatic hormone refractory 60 Hydroxyurea 60 Shows Promising 60 Solid Tumors 60 cetuximab Erbitux R 60 cediranib 60 Brentuximab Vedotin SGN 60 ENESTnd 60 Onalta 60 JAK2 inhibitor 60 Atripla combines 60 Etravirine 60 Atopic Dermatitis 60 Demonstrated Significant 60 unresectable tumors 60 FDA Accepts 60 Vaginal Gel 60 interferon gamma 1b 60 TBC# 60 Replacement Therapy 60 Akt inhibitor 60 Zoraxel 60 selective adenosine 60 administered intranasally 60 Warfarin Coumadin 60 OAB overactive bladder 60 Zeldox 60 guanfacine extended release 60 RAPAMUNE 60 pancreatic prostate 60 Ostabolin C 60 HCV NS5B polymerase 60 octreotide acetate 60 arginine vasopressin AVP 60 Aurora Kinase 60 recurrent herpes labialis 60 selective phosphodiesterase 60 Cloretazine R 60 AIR CF2 60 KRN# 60 Clevudine 60 Ovidrel 60 Hydralazine 60 taxane resistant 60 multicentre randomized controlled 60 somatostatin analog 60 Phase IIIb 60 evaluating satraplatin 60 urinary N telopeptide 60 THAT ARE DIFFICULT TO 60 Letairis ambrisentan 60 Vincristine 60 Kit CD# positive 60 constipation predominant irritable bowel 60 prucalopride 60 CIMZIA TM certolizumab pegol 60 Decompensated Heart Failure 60 Chronic Prostatitis 60 incretin mimetic 60 Naive Patients 60 Zoloft sertraline 60 Vfend 60 Doripenem 60 Edge STudy 60 Cervical Dystonia 60 hypercholesterolemic patients 60 transthyretin TTR mediated amyloidosis 60 Fungal Infections 60 Wellmune WGP 60 zoledronic acid Reclast 60 citalopram Celexa 60 D aspartate NMDA receptor 60 Oral Mucositis 60 Left Ventricular Dysfunction 60 Sanofi Pasteur Fluzone 60 inhalation powder 60 undergoing Percutaneous Coronary 60 Bevacizumab 60 Irinotecan 60 Boceprevir 60 Placebo controlled 60 Decitabine 60 azilsartan medoxomil 60 relapsed ALL 60 tazarotene 60 topically administered 60 Phase III Trial 60 mild vasodilator 60 Teriparatide 60 acitretin 60 Miconazole 60 Pegylated 60 Meta Analysis 60 DRUG ADMINISTRATION 60 sublingual tablets 60 ENDEAVOR IV 60 moderate hepatic impairment 60 Overactive Bladder OAB 60 receiving VELCADE 60 EFFEXOR XR 60 Diamyd r